Long Covid Ireland Coronavirus Health Long Covid Ireland

HIQA review finds no definitely effective Long Covid treatments

Reading now: 849
www.rte.ie

A major review of Long Covid by the Health Information and Quality Authority has found that no definitely effective treatments have yet been identified.

It says that Long Covid is a complex condition involving a wide range of symptoms that can be debilitating and vary significantly from person to person.

The most common symptoms include fatigue, cognitive impairment, memory loss and confusion, loss of smell and shortness of breath.

The report says that although some people will experience an improvement in their symptoms over time, some can experience symptoms lasting years.

Read more on rte.ie
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

COVID-19: the green book, chapter 14a - gov.uk
gov.uk
44%
533
COVID-19: the green book, chapter 14a
PDF, 746 KB, 57 pagesThis file may not be suitable for users of assistive technology.This chapter includes information on:Updated mention of a table.Updated to include JCVI advice on vaccination for children aged 6 months to 4 years in a clinical risk group.Updated storage information for VidPrevtyn.Updated to include shortened background, separation between the historical pandemic response and the ongoing programme, spring booster campaign, explanation of the end of universal primary and booster offers, and describing the move to only offer vaccine during seasonal campaigns.Updated to include approval of Pfizer bivalent vaccine and further clarification around vaccination of under 12 year olds.Updated to include information on the autumn programme and variant vaccines, and further clarification of information on revaccination and capillary leak syndrome.Updated to include: approval of Novavax, clarification around deferral after COVID-19 infection, one-off programme for 5 to 11 year olds who are not in clinical risk groups, advice on use of the paediatric formulation in those aged 12 years, spring booster recommendations (including flexibility around timing) and expectations for an autumn booster, clarification of the management of individuals with a history of allergic reactions, updated advice on management of people who have ITP following vaccination.Updated background to include latest data on vaccine effectiveness and booster safety; clarified and corrected chronology of booster advice.
DMCA